Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Rating of "Buy" by Analysts

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $16.14.

Several equities analysts recently weighed in on INZY shares. Needham & Company LLC reiterated a "buy" rating and set a $23.00 target price on shares of Inozyme Pharma in a research report on Friday. HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Inozyme Pharma in a research report on Friday. Wedbush restated an "outperform" rating and issued a $15.00 price objective on shares of Inozyme Pharma in a report on Monday, September 30th. Jefferies Financial Group restated a "buy" rating and issued a $17.00 price objective (up from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Finally, Stifel Nicolaus assumed coverage on Inozyme Pharma in a report on Thursday, September 12th. They issued a "buy" rating and a $16.00 price objective on the stock.

Inozyme Pharma Price Performance

Shares of NASDAQ:INZY traded down $0.12 on Friday, hitting $4.79. The company had a trading volume of 189,896 shares, compared to its average volume of 195,843. The company has a current ratio of 9.84, a quick ratio of 9.84 and a debt-to-equity ratio of 0.48. Inozyme Pharma has a 52-week low of $2.69 and a 52-week high of $7.80. The business has a 50 day moving average of $5.29 and a 200 day moving average of $4.95. The company has a market cap of $300.48 million, a PE ratio of -3.28 and a beta of 1.51.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). As a group, equities analysts anticipate that Inozyme Pharma will post -1.68 earnings per share for the current fiscal year.

Institutional Trading of Inozyme Pharma

Hedge funds have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C purchased a new position in Inozyme Pharma in the second quarter valued at about $52,000. Meeder Asset Management Inc. acquired a new stake in shares of Inozyme Pharma during the second quarter worth approximately $68,000. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma in the second quarter worth $76,000. SG Americas Securities LLC acquired a new stake in Inozyme Pharma in the third quarter valued at $81,000. Finally, Cubist Systematic Strategies LLC bought a new position in Inozyme Pharma during the 2nd quarter valued at $84,000. Hedge funds and other institutional investors own 88.30% of the company's stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.